# Bevacizumab and Trabectedin +/- Carboplatin in Advanced Ovarian Cancer

> **NCT01735071** · PHASE2 · COMPLETED · sponsor: **Mario Negri Institute for Pharmacological Research** · enrollment: 71 (actual)

## Conditions studied

- Ovarian Epithelial Cancer Recurrent

## Interventions

- **DRUG:** bevacizumab and trabectedin
- **DRUG:** bevacizumab, trabectedin and carboplatin

## Key facts

- **NCT ID:** NCT01735071
- **Lead sponsor:** Mario Negri Institute for Pharmacological Research
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2018-03-18
- **Final completion:** 2018-03-18
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2019-11-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01735071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01735071, "Bevacizumab and Trabectedin +/- Carboplatin in Advanced Ovarian Cancer". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT01735071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*